This trial is testing a new cell therapy for adults with solid tumors that have progressed after standard therapy. The therapy is derived from the patient's own tumor-infiltrating immune cells and is designed to increase activity against the tumor when it encounters a specific molecule on the tumor.
1 Primary · 4 Secondary · Reporting Duration: Up to 60 months
51 Total Participants · 2 Treatment Groups
Primary Treatment: ITIL-306 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Washington University School of Medicine||100.0%|